Analysis of Circulating Tumor mArkers in Blood 4 - ALCINA 4

Launched by INSTITUT CURIE · Oct 8, 2021

Keywords

ClinConnect Summary

The ALCINA 4 study is a research trial that looks at specific markers in the blood of patients with cancer. These markers can help doctors understand how the disease is progressing and how well treatments are working. The study will not change the standard treatments you already receive for your cancer; it simply adds a schedule for collecting blood samples over a period of 12 to 18 months. Each participant may have up to four blood samples taken, and if needed, one tumor sample may also be collected.

To be eligible for the study, participants must be at least 18 years old and currently receiving treatment for cancer at one of the participating centers. They should be able to give their consent to join the study and should not be under guardianship. The study is open to everyone, regardless of gender. If you are pregnant or breastfeeding, you may not be eligible depending on the specific group within the study. Overall, this trial aims to gather valuable information that could improve cancer care in the future while ensuring that your current treatment continues as normal.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patient treated for cancer at one of the participating center
• • 18 years old or higher
• • Signed informed consent form
• • Patient not deprived of their liberty or under guardianship (including temporary guardianship)
• • Patient covered by social security scheme
• • Patient with no compliance issue (related to geographical, social or psychological reasons) for study follow up
• • Other additional criteria will be defined (defining tumor type and clinical setting), by cohort
• If a biopsy tumor sample is to be taken:
• • Tumor considered as accessible by biopsy (at the investigator's discretion).
• • Normal blood coagulation tests (if applicable, and in case of a non-superficial tumor lesion).
• • No anticoagulant or antiaggregant treatment for the biopsy.
• Exclusion Criteria :
• • Pregnant and/or breast-feeding women depending on cohort.